The Cigna Group (CI)

Under the bull scenario, biosimilar adoption accelerates beyond management expectations, expanding specialty pharmacy margins. Commercial employer enrollment grows in Middle and Select markets, while transparent Evernorth Signature contracts scale rapidly with early adopters. Enterprise earnings compound at the upper end of management's 10-14% long-term target, driving valuation multiple expansion toward the high end of our fair value range ($825.00).

• Evernorth Specialty & Care Services pre-tax income expands above 15% annually driven by rapid biosimilar uptake.
• Cigna Healthcare medical care ratio remains disciplined near the favorable end of guided ranges, supported by commercial pricing power.
• Share repurchases retire 2.0% of diluted shares annually, driving EPS growth of 12-14%.